Ashkan Shoamanesh

Several PHRI trials will be presented at European Society of Cardiology (ESC) Congress 2022 in in Barcelona, Spain as well as online.

Sunday, August 28: Hot Line Session 5

    • PACIFIC-Stroke: Phase 2 program of anti-coagulation via inhibition of Facotr XIa by the oral compound BAY 2433334, a non-cardioembolic stroke study – PHRI Scientist Ashkan Shaomenesh
    • INVICTUS: Rivaroxaban versus VKA for rheumatic atrial fibrillation – Ganesan Karthikeyan (All India Institute of Medical Sciences), co-PI with PHRI Senior Scientist Stuart Connolly
Professor G. Karthikeyan, India

G. Karthikeyan

  • AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention – PHRI Scientist Mike Sharma

Monday, August 29: Hot Line Session 10

  • Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT) Outpatient Trial – PHRI Senior Scientist John Eikelboom
  • ACT Inpatient Trial – PHRI Scientist Sanjit Jolly

John Eikelboom

Other PHRI presentations at ESC 2022 include:

Back To Top